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Abstract
Bartter and Gitelman syndromes are rare genetic disorders in which there are specific 
defects in kidney function, characterized by metabolic alkalosis, hypokalemia, hyperrenin-
emia, and hyperaldosteronism, with or without hypomagnesemia. Blood pressure is nor-
mal or low in these patients. Positive diagnosis is one of the exclusions, and the difference 
between the two syndromes is based on urine calcium levels. Medication has to be taken 
lifelong. Renal transplantation can correct the transport defect in Bartter and Gitelman syn-
dromes. The symptoms and severity vary from one person to another and can range from 
mild to severe. Age of onset of overt symptoms can range from before birth to adulthood.
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1. Introduction
Bartter syndrome, originally described by Bartter and colleagues in 1962 [1], represents an auto-
somal recessive renal tubular disorder characterized by hypokalemia and metabolic alkalosis. 
In addition, patients have hyperreninemia and hyperplasia of the juxtaglomerular apparatus 
(the source of renin in the kidney) and secondary hyperaldosteronism [2]. The underlying 
renal abnormality results in excessive urinary losses of sodium, chloride, and potassium.
2. Etiology
Bartter and Gitelman syndromes are caused by the alteration of a carrier involved in sodium 
chloride (NaCl) reabsorption. This transporter is located in the thick ascending limb of the 
loop of Henle in Bartter syndrome and distal convoluted tubule in Gitelman syndrome [3].
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Bartter syndrome results from defective transepithelial transport of NaCl in the thick ascend-
ing loop or the distal convoluted tubule.
• Transepithelial Cl transport in the thick ascending loop depends on coordinated interplay 
between the luminal, bumetanide-sensitive, Na-K-2Cl co-transporter (NKCC2), the lumi-
nal, K channel (ROMK), the basolateral Cl channel (CIC-Kb), as well as other co-transport-
ers and channels [4].
• Chloride transport in the distal convoluted tubule occurs primarily via the luminal, thia-
zide-sensitive NaCl co-transporter [4].
There are six subtypes of Bartter syndrome (I, II, III, IV, IVB, and V), each corresponding to a 
genetic defect (Table 1).
Types I through IV—the severity and clinical presentation of Bartter syndrome varies with 
each type:
• Types I and II are the most severe disorders. They are characterized by polyhydramnios 
during pregnancy and premature birth. Those who survive infancy develop hypokalemia, 
metabolic alkalosis, polyuria, and hypercalciuria. Neonates with type II mutations that 
reduce activity of the renal outer medullary potassium channel (ROMK) often initially 
develop hyperkalemia [4]. However, as they mature, other potassium channels become 
active and contribute to the development of hypokalemia. Nephrocalcinosis is common in 
patients with these mutations and probably contributes to the late development of kidney 
dysfunction and, rarely, end-stage renal disease [5].
• The classic form of Bartter syndrome, type III, is less severe and presents later in life with 
hypokalemia, metabolic alkalosis, and hypercalciuria. The reduced severity of type III Bartter 
syndrome may be due to redundancy of chloride channels in the cells of the thick ascend-
ing limb. Loss of ClC-Kb activity causes the disease, but coexistent ClC-Ka activity may 
ameliorate the process. Some patients with ClC-Kb mutations usually have classic Bartter 
Bartter syndrome 
subtype
Genetic defect Clinical syndrome
Type I SLC12A1 (NKCC2) Antenatal Bartter syndrome
Type II KCNJ1 (ROMK) Antenatal Bartter syndrome
Type III CLCKB Classic Bartter syndrome
Type IV BSND Antenatal Bartter syndrome with congenital hearing loss
Type IV B CLCNKA
CLCNKB
Antenatal Bartter syndrome with congenital hearing loss
Type V CaSR Bartter syndrome with hypocalcaemia
Gitelman syndrome SLC12A3 (NCCT) Gitelman syndrome
Table 1. Bartter syndrome subtypes.
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syndrome that occurs in infancy or early childhood. It is characterized by hypomagnesemia, 
hypocalciuria (not hypercalciuria), and unresponsiveness to thiazide rather than loop diuret-
ics [6, 7]. This may be seen because ClC-Kb participates in chloride reabsorption along the 
distal convoluted tubule and connecting tubule, as well as the thick ascending limb [8]. Many 
of the mutations that cause Bartter syndrome type III destabilize channel structure, induce 
ClC-Kb retention within the endoplasmic reticulum, and accelerate channel degradation [6].
• Types IV and IVb have combined defects that involve both the ClC-Ka and ClC-Kb chan-
nels and cause severe disease, generally with antenatal presentation and congenital hearing 
loss. These two chloride channels are critical for normal ion transport in the stria vascularis 
of the inner ear and are vital to establish normal endocochlear potential differences [9–14]. 
Because of redundancy of function in the ear, hearing loss requires defects to exist in both 
ClC-Ka and ClC-Kb. This double defect can occur via at least two mechanisms:
 ○ As discussed above, the Barttin subunit is an important component of both channels. 
Thus, a single defect that affects the Barttin subunit reduces the function of both chan-
nels (type IV) [9–13]. Hereditary defect in Barttin leads to antenatal Bartter syndrome 
associated with sensorineural deafness and renal failure.
 ○ The other mechanism involves double mutations, which reduce the function of both 
ClC-Ka and ClC-Kb and thereby produce a phenotype similar to the Barttin type IV 
defect. This is generally called Bartter type IVb [15]. Although some have called this vari-
ant “Bartter type V disease,” the designation “type V Bartter disease” is most commonly 
used to describe a gain-of-function mutation in CaSR.
• Type V, usually called autosomal dominant hypocalcemia or autosomal dominant hypo-
parathyroidism, is due to a gain-of-function mutation in CaSR, encoding the calcium-
sensing receptor (CaSR) [16, 17]. In the parathyroid gland, this results in a downward 
“resetting” of the normal range for serum calcium. As a result, a lower-than-normal serum 
calcium concentration inhibits parathyroid hormone release, resulting in hypocalcemia.
The tubular defect found in Bartter syndrome is the same as in the chronic ingestion of loop 
diuretics, while in Gitelman syndrome, it is the same as in the chronic ingestion of thiazide 
diuretics. In both the syndromes, elevated salt removal will lead to volume depletion and 
activation of the renin-angiotensin-aldosterone system. The association of secondary hyper-
aldosteronism with increasing concentration of NaCl at the distal level leads to increased 
potassium and hydrogen secretion in collecting tubule and distal convoluted tubule, resulting 
in hypopotassemia and metabolic alkalosis.
The volume depletion explains why patients with Bartter or Gitelman syndrome have lower 
blood pressure than general population. In addition, in patients with Bartter syndrome, 
another possible cause of this phenomenon is increased prostaglandin renal clearance with a 
vasodilator effect [4]. Because urine dilution requires good functioning of the ascending por-
tion of the loop of Henle and the distal convoluted tubule, Bartter and Gitelman syndromes 
have a low urine dilution capacity [1].
There are also a number of distinct traits between the two syndromes caused by the different 
site of the NaCl reabsorption abnormality. Thus, patients with Bartter syndrome have a poor 
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response to the action of loop diuretics, while patients with Gitelman syndrome have a lower 
response to thiazide diuretics [4].
Calciuresis is normal or increased in Bartter syndrome, similar to loop diuretic effect. On the 
contrary, calciuresis is low in Gitelman syndrome, as in the use of thiazide diuretics.
3. Prevalence
Gitelman syndrome is a much more common disease than Bartter syndrome [18, 19]. For 
Gitelman syndrome, a prevalence of 1:40,000 is reported, while Bartter syndrome is less com-
mon in the population (1:1,000,000) [18]. The lower prevalence of Bartter syndrome in the 
population may be due at least in part to prenatal or neonatal death resulting from the disor-
der before it could be diagnosed [18].
4. Clinical manifestation
Table 2 summarizes the similar and distinct clinical features in Bartter and Gitelman syn-
dromes. In both the syndromes, clinical manifestations are less pronounced in heterozygotes.
Bartter syndrome I, II, IV, and IVB subtypes are most often severe early-onset disease, while 
subtypes III and V are lighter forms of late-onset disease. However, the correlation between 
the underlying genetic defect and the clinical phenotype is not absolute.
Subtypes I and II begin antenatally with polyhydramnios and prematurity. Patients who sur-
vive infancy develop hypokalemia, metabolic alkalosis, polyuria, and hypercalciuria.
Subtype III is the classic form of Bartter syndrome, starting later than the first subtypes with 
hypokalemia, metabolic alkalosis, and hypercalciuria. During the course of the disease, this 
subtype may be associated with proteinuria and renal failure.
Bartter syndrome Gitelman syndrome
It usually occurs in childhood It usually occurs in adolescents and adults
Growth retardation present Growth retardation absent
Normal or low blood pressure Normal or low blood pressure
Dehydration present Dehydration absent
Hypokalemic metabolic alkalosis Hypokalemic metabolic alkalosis
Polyuria and polydipsia present Polyuria and polydipsia absent
Normocalciuria or hypercalciuria Hypocalciuria
Maternal polyhydramnios common Maternal polyhydramnios absent
Normal or slightly low magnesium Hypomagnesemia
Table 2. Clinical features of Bartter and Gitelman syndromes.
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Subtypes IV and IVB usually begin antenatally and should be associated with neurosensory 
deafness, as the underlying genetic defect affects both NaCl conveying ion channels in the 
kidney and inner ear.
Subtype V is also known as autosomal-dominant hypocalcaemia or autosomal-dominant 
hypoparathyroidism. In this case, the underlying genetic defect leads to a “reset” of the nor-
mal serum calcium level. Thus, a lower value than normal can inhibit the secretion of parathy-
roid hormone, leading to hypocalcemia.
5. Differential diagnosis
• Other causes of unexplained hypokalemia and metabolic alkalosis
 ○ Vomiting/diarrhea
 ○ Diuretic abuse (Figure 1)
Figure 1. Differential diagnostic of metabolic alkalosis [20].
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6. Laboratory studies
• Serum potassium levels—low in all forms of Bartter syndrome
• Serum calcium levels—normal to low
• Serum magnesium levels—low or normal in Bartter syndrome, low in Gitelman syndrome
• Aldosterone levels—elevated
• Urinary potassium levels—elevated
• Urinary aldosterone levels—high
• Urinary chloride levels—high
7. Treatment
The tubular defects in Bartter syndrome cannot be corrected (except by renal transplanta-
tion). Thus, treatment is aimed at minimizing the effects of secondary increases in renin, aldo-
sterone, and, in some patients, prostaglandins, as well as correcting the volume deficit and 
electrolyte abnormalities. There is no consensus on the best treatment for Gitelman syndrome, 
and magnesium and potassium supplements are usually given.
7.1. NSAIDs and drugs that block distal convoluted tubule sodium-potassium 
exchange
Nonsteroidal anti-inflammatory drugs (NSAIDs) are an essential component of therapy and 
can ameliorate many of the abnormalities. The defect in the thick ascending limb of the loop 
of Henle function in Bartter syndrome often increases renal prostaglandin E2 (PGE2) produc-
tion. This also occurs with therapeutic loop diuretic use. Markedly increased PGE2 is com-
mon in patients with Bartter syndrome types I, II, IV, and IVb.
Indomethacin and celecoxib have been used; there are no clear advantages with either drug 
[21]. However, careful monitoring is required since NSAIDs can have significant adverse 
effects including renal and gastrointestinal toxicity.
In addition to an NSAID, a drug that blocks distal convoluted tubule sodium-potassium 
exchange, such as spironolactone, eplerenone, or amiloride, is usually administered, fre-
quently in higher-than-usual doses (up to 300, 150, and 40 mg/day, respectively). This regi-
men can raise the serum potassium, reverse the metabolic alkalosis, and partially correct the 
hypomagnesemia [21, 22]. Among patients with hypokalemia due to potassium wasting of 
any cause, drugs blocking distal sodium-potassium exchange are typically more effective and 
better tolerated than potassium supplementation alone.
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7.2. Angiotensin-converting enzyme inhibitors
Angiotensin-converting enzyme (ACE) inhibitors reduce the production of angiotensin II and 
aldosterone and may be a useful adjunctive therapy [23, 24].
Angiotensin receptor blockers (ARBs) should have similar efficacy but have not been well 
studied in these patients. ACE inhibitors will also reduce proteinuria in these patients when 
it exists [25].
7.3. Potassium and magnesium supplementation
Most patients require oral potassium and magnesium supplementation since therapy with 
NSAIDs and drugs that block distal convoluted tubule sodium-potassium exchange is often 
incompletely effective [26]. However, the restoration of normal serum potassium and mag-
nesium concentrations is often difficult to achieve for one or more of the following reasons:
• Blocking potassium secretion in the cortical collecting tubule with a drug that inhibits 
sodium-potassium exchange with or without an ACE inhibitor in patients with Bartter 
syndrome will not reverse the primary defect.
• Hypomagnesemia can contribute to urinary potassium loss.
• When hypokalemia and/or hypomagnesemia are due to urinary wasting, potassium or 
magnesium supplementation has limited efficacy. As the serum potassium and/or mag-
nesium falls in the untreated patient, the antikaliuretic effect of hypokalemia and the 
antimagnesiuretic effect of hypomagnesemia gradually reduce potassium and magnesium 
excretion until a new steady state is attained in which intake and urinary excretion are sim-
ilar and potassium and magnesium concentrations stabilize at a lower-than-normal level.
The rise in serum concentrations following the administration of potassium and magnesium 
supplements will reduce the stimulus to potassium and magnesium retention. As a result, 
most of the administered potassium or magnesium will be excreted in the urine. High doses, 
which are often difficult to tolerate (e.g., diarrhea with magnesium), are required to achieve 
a substantial elevation in serum potassium or magnesium. Similar considerations apply to 
hypokalemia and hypomagnesemia due to other causes of urinary wasting of these cations.
7.4. Renal transplantation
Renal transplantation corrects the transport abnormalities in Gitelman and Bartter syndromes, 
and recurrent disease in the transplant has not been described. Renal transplantation has been 
performed in rare patients who developed end-stage renal disease due to coexisting renal 
disease or the effects of chronic volume depletion, electrolyte abnormalities, drug-related side 
effects, and/or nephrocalcinosis [27, 28]. In addition, successful preemptive bilateral nephrec-
tomy and renal transplantation have been performed in two patients with severe neonatal 
Bartter syndrome [28].
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